Fennec Pharmaceuticals Inc.
NASDAQ•FENC
CEO: Mr. Rostislav Raykov
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2017-09-15
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Contact Information
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, 27709, United States
919-636-4530
Market Cap
$257.22M
P/E (TTM)
-36.9
24.5
Dividend Yield
--
52W High
$10.45
52W Low
$5.65
52W Range
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data